Alnylam Rockets On 'Best-Case Scenario' For Pfizer-Rivaling Heart Drug - Investor's Business Daily

The companies are working on treatments for ATTR amyloidosis with cardiomyopathy.

By: Investor's Business Daily

Jun 26 2024
0
0 Views

Alnylam stock catapulted Monday, breaking out from a lengthy consolidation, after its experimental heart-disease treatment topped expectations in a highly anticipated study. XNOW PLAYINGCRSP Stock O… [+2918 chars]

Andreessen Horowitz plans to launch a private equity fund, documents show - Fortune

Grail prepares for public debut, and challenges of going independent, after spinoff from Illumina - Endpoints News

Mt. Gox Trustee Announces Definitive Date For Bitcoin And BCH Repayments | Bitcoinist.com - Bitcoinist

Hooters abruptly shuts dozens of 'underperforming stores' as inflation hammers diners - New York Post

Automakers call for 'practically impossible' automatic emergency braking rule to be reconsidered - Fox Business

Car dealerships in North America revert to pens and paper after cyberattacks on software provider - The Associated Press

Share this page

Guest Posts by Easy Branches

Banner advertising on easybranches network